Anticytokine therapy in neuropathic pain management

References

• George A, Bühl A, Sommer C. Wallerian degeneration after crush injury of rat sciatic nerve increases endo- and epineurial tumor necrosis factor-α protein. Neurosci. Lett.372(3), 215–219 (2004).
   PubMed Web of Science ®Google Scholar
• Kleinschnitz C, Brinkhoff J, Zelenka M, Sommer C, Stoll G. The extent of cytokine induction in peripheral nerve lesions depends on the mode of injury and NMDA receptor signaling. J. Neuroimmunol.149(1–2), 77–83 (2004).
   PubMedGoogle Scholar
• Murphy PG, Ramer MS, Borthwick L et al. Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides associated with chronic nerve constriction in mice. Eur. J. Neurosci.11(7), 2243–2253 (1999).
   PubMed Web of Science ®Google Scholar
• Okamoto K, Martin DP, Schmelzer JD, Mitsui Y, Low PA. Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp. Neurol.169(2), 386–391 (2001).
   PubMed Web of Science ®Google Scholar
• Wagner R, Myers RR. Schwann cells produce tumor necrosis factor α: expression in injured and non-injured nerves. Neuroscience73(3), 625–629 (1996).
   PubMed Web of Science ®Google Scholar
• Murphy PG, Grondin J, Altares M, Richardson PM. Induction of interleukin-6 in axotomized sensory neurons. J. Neurosci.15(7 Pt 2), 5130–5138 (1995).
   PubMed Web of Science ®Google Scholar
• Schäfers M, Geis C, Svensson CI, Luo ZD, Sommer C. Selective increase of tumour necrosis factor-α in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur. J. Neurosci.17(4), 791–804 (2003).
   PubMed Web of Science ®Google Scholar
• Arruda JL, Colburn RW, Rickman AJ, Rutkowski MD, DeLeo JA. Increase of interleukin-6 mRNA in the spinal cord following peripheral nerve injury in the rat: potential role of IL-6 in neuropathic pain. Brain Res. Mol. Brain Res.62(2), 228–235 (1998).
   PubMedGoogle Scholar
• DeLeo JA, Colburn RW, Nichols M, Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J. Interferon Cytokine Res.16(9), 695–700 (1996).
   PubMed Web of Science ®Google Scholar
• DeLeo JA, Colburn RW, Rickman AJ. Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res.759(1), 50–57 (1997).
   PubMed Web of Science ®Google Scholar
• Hashizume H, Rutkowski MD, Weinstein JN, DeLeo JA. Central administration of methotrexate reduces mechanical allodynia in an animal model of radiculopathy/sciatica. Pain87(2), 159–169 (2000).
   PubMedGoogle Scholar
• Winkelstein BA, DeLeo JA. Nerve root injury severity differentially modulates spinal glial activation in a rat lumbar radiculopathy model: considerations for persistent pain. Brain Res.956(2), 294–301 (2002).
   PubMed Web of Science ®Google Scholar
• Raghavendra V, Tanga F, Rutkowski MD, DeLeo JA. Anti-hyperalgesic and morphine-sparing actions of propentofylline following peripheral nerve injury in rats: mechanistic implications of spinal glia and proinflammatory cytokines. Pain104(3), 655–664 (2003).
   PubMed Web of Science ®Google Scholar
• Winkelstein BA, Rutkowski MD, Sweitzer SM, Pahl JL, DeLeo JA. Nerve injury proximal or distal to the DRG induces similar spinal glial activation and selective cytokine expression but differential behavioral responses to pharmacologic treatment. J. Comp. Neurol.439(2), 127–139 (2001).
   PubMed Web of Science ®Google Scholar
• Milligan ED, Mehmert KK, Hinde JL et al. Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120. Brain Res.861(1), 105–116 (2000).
   PubMedGoogle Scholar
• Milligan ED, O’Connor KA, Nguyen KT et al. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J. Neurosci.21(8), 2808–2819 (2001).
   PubMed Web of Science ®Google Scholar
• Watkins LR, Hutchinson MR, Ledeboer A et al. Norman Cousins Lecture. Glia as the “bad guys”: implications for improving clinical pain control and the clinical utility of opioids. Brain Behav. Immun.21(2), 131–146 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson LC, Rao RD. Interleukin-6 and nerve growth factor levels in peripheral nerve and brainstem after trigeminal nerve injury in the rat. Arch. Oral Biol.46(7), 633–640 (2001).
   PubMedGoogle Scholar
• Vania Apkarian A, Lavarello S, Randolf A et al. Expression of IL-1β in supraspinal brain regions in rats with neuropathic pain. Neurosci. Lett.407(2), 176–181 (2006).
   PubMed Web of Science ®Google Scholar
• Covey WC, Ignatowski TA, Renauld AE et al. Expression of neuron-associated tumor necrosis factor α in the brain is increased during persistent pain. Reg. Anesth. Pain Med.27(4), 357–366 (2002).
   PubMedGoogle Scholar
• Spengler RN, Sud R, Knight PR, Ignatowski TA. Antinociception mediated by α2-adrenergic activation involves increasing tumor necrosis factor α (TNFα) expression and restoring TNFα and α2-adrenergic inhibition of norepinephrine release. Neuropharmacology52(2), 576–589 (2007).
   PubMed Web of Science ®Google Scholar
• Covey WC, Ignatowski TA, Knight PR, Spengler RN. Brain-derived TNFα: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res.859(1), 113–122 (2000).
   PubMed Web of Science ®Google Scholar
• Ignatowski TA, Covey WC, Knight PR et al. Brain-derived TNFα mediates neuropathic pain. Brain Res.841(1–2), 70–77 (1999).
   PubMed Web of Science ®Google Scholar
• Liu J, Feng X, Yu M et al. Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci. Lett.412(3), 268–272 (2007).
   PubMed Web of Science ®Google Scholar
• Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH. The pivotal role of tumour necrosis factor α in the development of inflammatory hyperalgesia. Br. J. Pharmacol.107(3), 660–664 (1992).
   PubMed Web of Science ®Google Scholar
• Perkins MN, Kelly D, Davis AJ. Bradykinin B1 and B2 receptor mechanisms and cytokine-induced hyperalgesia in the rat. Can. J. Physiol. Pharmacol.73(7), 832–836 (1995).
   PubMed Web of Science ®Google Scholar
• Junger H, Sorkin LS. Nociceptive and inflammatory effects of subcutaneous TNFα. Pain85(1–2), 145–151 (2000).
   PubMed Web of Science ®Google Scholar
• Sorkin LS, Xiao WH, Wagner R, Myers RR. Tumour necrosis factor-α induces ectopic activity in nociceptive primary afferent fibres. Neuroscience81(1), 255–262 (1997).
   PubMed Web of Science ®Google Scholar
• Wagner R, Myers RR. Endoneurial injection of TNF-α produces neuropathic pain behaviors. Neuroreport7(18), 2897–2901 (1996).
   PubMed Web of Science ®Google Scholar
• Zelenka M, Schäfers M, Sommer C. Intraneural injection of interleukin-1β and tumor necrosis factor-α into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain116(3), 257–263 (2005).
   PubMed Web of Science ®Google Scholar
• Liu B, Li H, Brull SJ, Zhang JM. Increased sensitivity of sensory neurons to tumor necrosis factor α in rats with chronic compression of the lumbar ganglia. J. Neurophysiol.88(3), 1393–1399 (2002).
   PubMed Web of Science ®Google Scholar
• Ozaktay AC, Kallakuri S, Takebayashi T et al. Effects of interleukin-1β, interleukin-6, and tumor necrosis factor on sensitivity of dorsal root ganglion and peripheral receptive fields in rats. Eur. Spine J.15(10), 1529–1537 (2006).
   PubMed Web of Science ®Google Scholar
• Schäfers M, Lee DH, Brors D, Yaksh TL, Sorkin LS. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-α after spinal nerve ligation. J. Neurosci.23(7), 3028–3038 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang JM, Li H, Liu B, Brull SJ. Acute topical application of tumor necrosis factor α evokes protein kinase A-dependent responses in rat sensory neurons. J. Neurophysiol.88(3), 1387–1392 (2002).
   PubMed Web of Science ®Google Scholar
• Falchi M, Ferrara F, Gharib C, Dib B. Hyperalgesic effect of intrathecally administered interleukin-1 in rats. Drugs Exp. Clin. Res.27(3), 97–101 (2001).
   PubMedGoogle Scholar
• Reeve AJ, Patel S, Fox A, Walker K, Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur. J. Pain4(3), 247–257 (2000).
   PubMed Web of Science ®Google Scholar
• Sung CS, Wen ZH, Chang WK et al. Intrathecal interleukin-1β administration induces thermal hyperalgesia by activating inducible nitric oxide synthase expression in the rat spinal cord. Brain Res.1015(1–2), 145–153 (2004).
   PubMedGoogle Scholar
• Hori T, Oka T, Hosoi M, Aou S. Pain modulatory actions of cytokines and prostaglandin E2 in the brain. Ann. NY Acad. Sci.840, 269–281 (1998).
   PubMedGoogle Scholar
• Fukuoka H, Kawatani M, Hisamitsu T, Takeshige C. Cutaneous hyperalgesia induced by peripheral injection of interleukin-1β in the rat. Brain Res.657(1–2), 133–140 (1994).
   PubMedGoogle Scholar
• Opree A, Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-α, IL-1β, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. J. Neurosci.20(16), 6289–6293 (2000).
   PubMed Web of Science ®Google Scholar
• Obreja O, Rathee PK, Lips KS, Distler C, Kress M. IL-1β potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C. FASEB J.16(12), 1497–1503 (2002).
   PubMedGoogle Scholar
• Lindholm D, Heumann R, Meyer M, Thoenen H. Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature330(6149), 658–659 (1987).
   PubMed Web of Science ®Google Scholar
• Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ. Contribution of interleukin-1 β to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br. J. Pharmacol.115(7), 1265–1275 (1995).
   PubMed Web of Science ®Google Scholar
• Inoue A, Ikoma K, Morioka N et al. Interleukin-1β induces substance P release from primary afferent neurons through the cyclooxygenase-2 system. J. Neurochem.73(5), 2206–2213 (1999).
   PubMed Web of Science ®Google Scholar
• Thompson SW, Priestley JV, Southall A. gp130 cytokines, leukemia inhibitory factor and interleukin-6, induce neuropeptide expression in intact adult rat sensory neurons in vivo: time-course, specificity and comparison with sciatic nerve axotomy. Neuroscience84(4), 1247–1255 (1998).
   PubMedGoogle Scholar
• Sorkin LS, Doom CM. Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake rat. J. Peripher. Nerv. Syst.5(2), 96–100 (2000).
   PubMed Web of Science ®Google Scholar
• Ozaktay AC, Cavanaugh JM, Asik I, DeLeo JA, Weinstein JN. Dorsal root sensitivity to interleukin-1 β, interleukin-6 and tumor necrosis factor in rats. Eur. Spine J.11(5), 467–475 (2002).
   PubMedGoogle Scholar
• Cuellar JM, Montesano PX, Carstens E. Role of TNF-α in sensitization of nociceptive dorsal horn neurons induced by application of nucleus pulposus to L5 dorsal root ganglion in rats. Pain110(3), 578–587 (2004).
   PubMedGoogle Scholar
• Onda A, Hamba M, Yabuki S, Kikuchi S. Exogenous tumor necrosis factor-α induces abnormal discharges in rat dorsal horn neurons. Spine27(15), 1618–1624; discussion 1624 (2002).
   PubMedGoogle Scholar
• Onda A, Yabuki S, Kikuchi S. Effects of neutralizing antibodies to tumor necrosis factor-α on nucleus pulposus-induced abnormal nociresponses in rat dorsal horn neurons. Spine28(10), 967–972 (2003).
   PubMedGoogle Scholar
• MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal.14(6), 477–492 (2002).
   PubMed Web of Science ®Google Scholar
• Dubovy P, Jancalek R, Klusakova I, Svizenska I, Pejchalova K. Intra- and extraneuronal changes of immunofluorescence staining for TNF- and TNFR1 in the dorsal root ganglia of rat peripheral neuropathic pain models. Cell. Mol. Neurobiol.26(7–8), 1205–1217 (2006).
   PubMedGoogle Scholar
• George A, Buehl A, Sommer C. Tumor necrosis factor receptor 1 and 2 proteins are differentially regulated during Wallerian degeneration of mouse sciatic nerve. Exp. Neurol.192(1), 163–166 (2005).
   PubMedGoogle Scholar
• Ohtori S, Takahashi K, Moriya H, Myers RR. TNF-α and TNF-α receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. Spine29(10), 1082–1088 (2004).
   PubMed Web of Science ®Google Scholar
• Schäfers M, Sorkin LS, Geis C, Shubayev VI. Spinal nerve ligation induces transient upregulation of tumor necrosis factor receptors 1 and 2 in injured and adjacent uninjured dorsal root ganglia in the rat. Neurosci. Lett.347(3), 179–182 (2003).
   PubMed Web of Science ®Google Scholar
• Xu JT, Xin WJ, Zang Y, Wu CY, Liu XG. The role of tumor necrosis factor-α in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. Pain123(3), 306–321 (2006).
   PubMed Web of Science ®Google Scholar
• Holmes GM, Hebert SL, Rogers RC, Hermann GE. Immunocytochemical localization of TNF type 1 and type 2 receptors in the rat spinal cord. Brain Res.1025(1–2), 210–219 (2004).
   PubMed Web of Science ®Google Scholar
• Pollock J, McFarlane SM, Connell MC et al. TNF-α receptors simultaneously activate Ca2+ mobilisation and stress kinases in cultured sensory neurones. Neuropharmacology42(1), 93–106 (2002).
   PubMed Web of Science ®Google Scholar
• Jin X, Gereau RWT. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-α. J. Neurosci.26(1), 246–255 (2006).
   PubMed Web of Science ®Google Scholar
• Takahashi N, Kikuchi S, Shubayev VI, Campana WM, Myers RR. TNF-α and phosphorylation of ERK in DRG and spinal cord: insights into mechanisms of sciatica. Spine31(5), 523–529 (2006).
   PubMed Web of Science ®Google Scholar
• Diem R, Meyer R, Weishaupt JH, Bahr M. Reduction of potassium currents and phosphatidylinositol 3-kinase-dependent AKT phosphorylation by tumor necrosis factor-α rescues axotomized retinal ganglion cells from retrograde cell death in vivo. J. Neurosci.21(6), 2058–2066 (2001).
   PubMed Web of Science ®Google Scholar
• Furukawa K, Mattson MP. The transcription factor NF-κB mediates increases in calcium currents and decreases in NMDA- and AMPA/kainate-induced currents induced by tumor necrosis factor-α in hippocampal neurons. J. Neurochem.70(5), 1876–1886 (1998).
   PubMed Web of Science ®Google Scholar
• Soliven B, Albert J. Tumor necrosis factor modulates Ca2+ currents in cultured sympathetic neurons. J. Neurosci.12(7), 2665–2671 (1992).
   PubMedGoogle Scholar
• Baldwin RL, Stolowitz ML, Hood L, Wisnieski BJ. Structural changes of tumor necrosis factor α associated with membrane insertion and channel formation. Proc. Natl Acad. Sci. USA93(3), 1021–1026 (1996).
   PubMedGoogle Scholar
• Kagan BL, Baldwin RL, Munoz D, Wisnieski BJ. Formation of ion-permeable channels by tumor necrosis factor-α. Science255(5050), 1427–1430 (1992).
   PubMed Web of Science ®Google Scholar
• Ignatowski TA, Sud R, Reynolds JL, Knight PR, Spengler RN. The dissipation of neuropathic pain paradoxically involves the presence of tumor necrosis factor-α (TNF). Neuropharmacology48(3), 448–460 (2005).
   PubMedGoogle Scholar
• Reynolds JL, Ignatowski TA, Gallant S, Spengler RN. Amitriptyline administration transforms tumor necrosis factor-α regulation of norepinephrine release in the brain. Brain Res.1023(1), 112–120 (2004).
   PubMedGoogle Scholar
• Reynolds JL, Ignatowski TA, Sud R, Spengler RN. Brain-derived tumor necrosis factor-α and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant. J. Pharmacol. Exp. Ther.310(3), 1216–1225 (2004).
   PubMedGoogle Scholar
• Reynolds JL, Ignatowski TA, Sud R, Spengler RN. An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-α production culminating in increases in noradrenergic neurotransmission. Neuroscience133(2), 519–531 (2005).
   PubMed Web of Science ®Google Scholar
• Sud R, Ignatowski TA, Lo CP, Spengler RN. Uncovering molecular elements of brain–body communication during development and treatment of neuropathic pain. Brain Behav. Immun.21(1), 112–124 (2007).
   PubMedGoogle Scholar
• Renauld AE, Spengler RN. Tumor necrosis factor expressed by primary hippocampal neurons and SH-SY5Y cells is regulated by α2-adrenergic receptor activation. J. Neurosci. Res.67(2), 264–274 (2002).
   PubMedGoogle Scholar
• Reynolds JL, Ignatowski TA, Spengler RN. Effect of tumor necrosis factor-α on the reciprocal G-protein-induced regulation of norepinephrine release by the α2-adrenergic receptor. J. Neurosci. Res.79(6), 779–787 (2005).
   PubMed Web of Science ®Google Scholar
• Nicol GD, Lopshire JC, Pafford CM. Tumor necrosis factor enhances the capsaicin sensitivity of rat sensory neurons. J. Neurosci.17(3), 975–982 (1997).
   PubMedGoogle Scholar
• Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain118(3), 289–305 (2005).
   PubMed Web of Science ®Google Scholar
• Ignatowski TA, Noble BK, Wright JR et al. Neuronal-associated tumor necrosis factor (TNF α): its role in noradrenergic functioning and modification of its expression following antidepressant drug administration. J. Neuroimmunol.79(1), 84–90 (1997).
   PubMedGoogle Scholar
• Tai YH, Wang YH, Wang JJ et al. Amitriptyline suppresses neuroinflammation and up-regulates glutamate transporters in morphine-tolerant rats. Pain124(1–2), 77–86 (2006).
   PubMed Web of Science ®Google Scholar
• Wu WP, Hao JX, Ongini E et al. A nitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury. Br. J. Pharmacol.141(1), 65–74 (2004).
   PubMed Web of Science ®Google Scholar
• Beyreuther BK, Geis C, Stöhr T, Sommer C. Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. Neuropharmacology52(5), 1312–1317 (2007).
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Graf A, Sfikas N. The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur. J. Pain10(6), 567–571 (2006).
   PubMed Web of Science ®Google Scholar
• George A, Marziniak M, Schäfers M, Toyka KV, Sommer C. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-α, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain88(3), 267–275 (2000).
   PubMed Web of Science ®Google Scholar
• Lindenlaub T, Teuteberg P, Hartung T, Sommer C. Effects of neutralizing antibodies to TNF-α on pain-related behavior and nerve regeneration in mice with chronic constriction injury. Brain Res.866(1–2), 15–22 (2000).
   PubMedGoogle Scholar
• Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp. Neurol.151(1), 138–142 (1998).
   PubMed Web of Science ®Google Scholar
• Schäfers M, Brinkhoff J, Neukirchen S, Marziniak M, Sommer C. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-α and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci. Lett.310(2–3), 113–116 (2001).
   PubMed Web of Science ®Google Scholar
• Watkins LR, Wiertelak EP, Goehler LE et al. Neurocircuitry of illness-induced hyperalgesia. Brain Res.639(2), 283–299 (1994).
   PubMed Web of Science ®Google Scholar
• Milligan ED, Twining C, Chacur M et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J. Neurosci.23(3), 1026–1040 (2003).
   PubMed Web of Science ®Google Scholar
• Sweitzer S, Martin D, DeLeo JA. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience103(2), 529–539 (2001).
   PubMed Web of Science ®Google Scholar
• Parada CA, Yeh JJ, Joseph EK, Levine JD. Tumor necrosis factor receptor type-1 in sensory neurons contributes to induction of chronic enhancement of inflammatory hyperalgesia in rat. Eur. J. Neurosci.17(9), 1847–1852 (2003).
   PubMedGoogle Scholar
• Vogel C, Stallforth S, Sommer C. Altered pain behavior and regeneration after nerve injury in TNF receptor deficient mice. J. Peripher. Nerv. Syst.11(4), 294–303 (2006).
   PubMedGoogle Scholar
• Cunha TM, Verri WA, Jr., Silva JS et al. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc. Natl Acad. Sci. USA102(5), 1755–1760 (2005).
   PubMed Web of Science ®Google Scholar
• Schäfers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-α induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J. Neurosci.23(7), 2517–2521 (2003).
   PubMed Web of Science ®Google Scholar
• Sommer C, Schäfers M, Marziniak M, Toyka KV. Etanercept reduces hyperalgesia in experimental painful neuropathy. J. Peripher. Nerv. Syst.6(2), 67–72 (2001).
   PubMed Web of Science ®Google Scholar
• Olmarker K, Nutu M, Storkson R. Changes in spontaneous behavior in rats exposed to experimental disc herniation are blocked by selective TNF-α inhibition. Spine28(15), 1635–1641; discussion 1642 (2003).
   PubMed Web of Science ®Google Scholar
• Hao S, Mata M, Glorioso JC, Fink DJ. Gene transfer to interfere with TNFα signaling in neuropathic pain. Gene Ther.14(13), 1010–1016 (2007).
   PubMed Web of Science ®Google Scholar
• Le Buanec H, Delavallee L, Bessis N et al. TNFα kinoid vaccination-induced neutralizing antibodies to TNFα protect mice from autologous TNFα-driven chronic and acute inflammation. Proc. Natl Acad. Sci. USA103(51), 19442–19447 (2006).
   PubMed Web of Science ®Google Scholar
• Sommer C, Petrausch S, Lindenlaub T, Toyka KV. Neutralizing antibodies to interleukin 1-receptor reduce pain associated behavior in mice with experimental neuropathy. Neurosci. Lett.270(1), 25–28 (1999).
   PubMed Web of Science ®Google Scholar
• Laughlin TM, Bethea JR, Yezierski RP, Wilcox GL. Cytokine involvement in dynorphin-induced allodynia. Pain84(2–3), 159–167 (2000).
   PubMed Web of Science ®Google Scholar
• Ledeboer A, Jekich BM, Sloane EM et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav. Immun.21(5), 686–698 (2007).
   PubMed Web of Science ®Google Scholar
• Honore P, Wade CL, Zhong C et al. Interleukin-1αβ gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain. Behav Brain Res.167(2), 355–364 (2006).
   PubMedGoogle Scholar
• Wolf G, Gabay E, Tal M, Yirmiya R, Shavit Y. Genetic impairment of interleukin-1 signaling attenuates neuropathic pain, autotomy, and spontaneous ectopic neuronal activity, following nerve injury in mice. Pain120(3), 315–324 (2006).
   PubMedGoogle Scholar
• Arruda JL, Sweitzer S, Rutkowski MD, DeLeo JA. Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain. Brain Res.879(1–2), 216–225 (2000).
   PubMed Web of Science ®Google Scholar
• Ramer MS, Murphy PG, Richardson PM, Bisby MA. Spinal nerve lesion-induced mechanoallodynia and adrenergic sprouting in sensory ganglia are attenuated in interleukin-6 knockout mice. Pain78(2), 115–121 (1998).
   PubMed Web of Science ®Google Scholar
• Xu XJ, Hao JX, Andell-Jonsson S et al. Nociceptive responses in interleukin-6-deficient mice to peripheral inflammation and peripheral nerve section. Cytokine9(12), 1028–1033 (1997).
   PubMed Web of Science ®Google Scholar
• Ma W, Quirion R. Increased calcitonin gene-related peptide in neuroma and invading macrophages is involved in the up-regulation of interleukin-6 and thermal hyperalgesia in a rat model of mononeuropathy. J. Neurochem.98(1), 180–192 (2006).
   PubMedGoogle Scholar
• Flatters SJ, Fox AJ, Dickenson AH. Spinal interleukin-6 (IL-6) inhibits nociceptive transmission following neuropathy. Brain Res.984(1–2), 54–62 (2003).
   PubMed Web of Science ®Google Scholar
• Flatters SJ, Fox AJ, Dickenson AH. Nerve injury alters the effects of interleukin-6 on nociceptive transmission in peripheral afferents. Eur. J. Pharmacol.484(2–3), 183–191 (2004).
   PubMedGoogle Scholar
• Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals14(4), 166–174 (2005).
   PubMedGoogle Scholar
• Hao S, Mata M, Glorioso JC, Fink DJ. HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol. Pain2, 6 (2006).
   PubMed Web of Science ®Google Scholar
• Tu H, Juelich T, Smith EM et al. Evidence for endogenous interleukin-10 during nociception. J. Neuroimmunol.139(1–2), 145–149 (2003).
   PubMedGoogle Scholar
• Wagner R, Janjigian M, Myers RR. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-α expression. Pain74(1), 35–42 (1998).
   PubMed Web of Science ®Google Scholar
• Poole S, Cunha FQ, Selkirk S, Lorenzetti BB, Ferreira SH. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. Br. J. Pharmacol.115(4), 684–688 (1995).
   PubMed Web of Science ®Google Scholar
• Yao MZ, Gu JF, Wang JH et al. Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience112(2), 409–416 (2002).
   PubMed Web of Science ®Google Scholar
• Yao MZ, Gu JF, Wang JH et al. Adenovirus-mediated interleukin-2 gene therapy of nociception. Gene Ther.10(16), 1392–1399 (2003).
   PubMed Web of Science ®Google Scholar
• Ledeboer A, Wierinckx A, Bol JG et al. Regional and temporal expression patterns of interleukin-10, interleukin-10 receptor and adhesion molecules in the rat spinal cord during chronic relapsing EAE. J. Neuroimmunol.136(1–2), 94–103 (2003).
   PubMedGoogle Scholar
• Milligan ED, Langer SJ, Sloane EM et al. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur. J. Neurosci.21(8), 2136–2148 (2005).
   PubMed Web of Science ®Google Scholar
• Milligan ED, Sloane EM, Langer SJ et al. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol. Pain1(1), 9 (2005).
   PubMed Web of Science ®Google Scholar
• Svensson CI, Schäfers M, Jones TL, Powell H, Sorkin LS. Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci. Lett.379(3), 209–213 (2005).
   PubMed Web of Science ®Google Scholar
• Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J. Neurosci.23(10), 4017–4022 (2003).
   PubMed Web of Science ®Google Scholar
• Xu M, Bruchas MR, Ippolito DL, Gendron L, Chavkin C. Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by kappa opioid activation of p38 mitogen-activated protein kinase. J. Neurosci.27(10), 2570–2581 (2007).
   PubMedGoogle Scholar
• Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor-α and interleukin-1β during leprosy reactional states. Clin. Exp. Immunol.84(1), 103–108 (1991).
   PubMed Web of Science ®Google Scholar
• Barnes PF, Chatterjee D, Brennan PJ, Rea TH, Modlin RL. Tumor necrosis factor production in patients with leprosy. Infect. Immun.60(4), 1441–1446 (1992).
   PubMed Web of Science ®Google Scholar
• Apfel SC, Zochodne DW. Thalidomide neuropathy: too much or too long? Neurology62(12), 2158–2159 (2004).
   PubMed Web of Science ®Google Scholar
• Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent erythema nodosum leprosum with infliximab. N. Engl. J. Med.355(7), 739 (2006).
   PubMed Web of Science ®Google Scholar
• Empl M, Renaud S, Erne B et al. TNF-α expression in painful and nonpainful neuropathies. Neurology56(10), 1371–1377 (2001).
   PubMed Web of Science ®Google Scholar
• Lindenlaub T, Sommer C. Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol. (Berl)105(6), 593–602 (2003).
   PubMed Web of Science ®Google Scholar
• Üçeyler N, Rogausch JP, Toyka KV, Sommer C. Differential expression of cytokines in painful and painless neuropathies. Neurology69(1), 42–49 (2007).
   PubMed Web of Science ®Google Scholar
• van Doorn PA, Ruts L. Treatment of chronic inflammatory demyelinating polyneuropathy. Curr. Opin. Neurol.17(5), 607–613 (2004).
   PubMedGoogle Scholar
• Ching DW, McClintock A, Beswick F. Successful treatment with low-dose thalidomide in a patient with both Behcet’s disease and complex regional pain syndrome type I: case report. J. Clin. Rheumatol.9(2), 96–98 (2003).
   PubMed Web of Science ®Google Scholar
• Huygen FJ, Niehof S, Zijlstra FJ, van Hagen PM, van Daele PL. Successful treatment of CRPS 1 with anti-TNF. J. Pain Symptom Manage.27(2), 101–103 (2004).
   PubMed Web of Science ®Google Scholar
• Munnikes RJ, Muis C, Boersma M et al. Intermediate stage complex regional pain syndrome type 1 is unrelated to proinflammatory cytokines. Mediators Inflamm.2005(6), 366–372 (2005).
   PubMedGoogle Scholar
• Maihöfner C, Handwerker HO, Neundorfer B, Birklein F. Mechanical hyperalgesia in complex regional pain syndrome: a role for TNF-α? Neurology65(2), 311–313 (2005).
   PubMed Web of Science ®Google Scholar
• Kotani N, Kudo R, Sakurai Y et al. Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. Am. J. Med.116(5), 318–324 (2004).
   Google Scholar
• Rotty J, Heinzerling L, Schurmann D, Suttorp N. Interleukin-2: a potential treatment option for postherpetic neuralgia? Clin. Infect. Dis.43(12), E109–E110 (2006).
   PubMedGoogle Scholar
• Ahn SH, Cho YW, Ahn MW et al. mRNA expression of cytokines and chemokines in herniated lumbar intervertebral discs. Spine27(9), 911–917 (2002).
   PubMed Web of Science ®Google Scholar
• Brisby H, Olmarker K, Larsson K, Nutu M, Rydevik B. Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur. Spine J.11(1), 62–66 (2002).
   PubMed Web of Science ®Google Scholar
• Burke JG, Watson RW, McCormack D et al. Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. J. Bone Joint Surg. Br.84(2), 196–201 (2002).
   PubMedGoogle Scholar
• Tobinick EL, Britschgi-Davoodifar S. Perispinal TNF-α inhibition for discogenic pain. Swiss Med. Wkly133(11–12), 170–177 (2003).
   PubMed Web of Science ®Google Scholar
• Korhonen T, Karppinen J, Paimela L et al. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. Spine31(24), 2759–2766 (2006).
   PubMed Web of Science ®Google Scholar
• Genevay S, Guerne PA, Gabay C. Efficacy of tumor necrosis factor-α blockade for severe sciatica? Rev. Med. Suisse Romande124(9), 543–545 (2004).
   PubMedGoogle Scholar
• Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N. Engl. J. Med.346(18), 1349–1356 (2002).
   PubMed Web of Science ®Google Scholar
• Karppinen J, Korhonen T, Malmivaara A et al. Tumor necrosis factor-α monoclonal antibody, infliximab, used to manage severe sciatica. Spine28(8), 750–753; discussion 753–754 (2003).
   PubMed Web of Science ®Google Scholar
• Mansfield JC, Parkes M, Hawthorne AB et al. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease. Aliment Pharmacol. Ther.26(3), 421–430 (2007).
   PubMed Web of Science ®Google Scholar
• Sweitzer SM, DeLeo JA. The active metabolite of leflunomide, an immunosuppressive agent, reduces mechanical sensitivity in a rat mononeuropathy model. J. Pain3(5), 360–368 (2002).
   PubMedGoogle Scholar
• Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain. Nat. Rev. Drug Discov.2(12), 973–985 (2003).
   PubMed Web of Science ®Google Scholar
• Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin. Investig. Drugs16(7), 935–950 (2007).
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor-α blockers etanercept, infliximab and adalimumab. J. Dermatol. Treat.15(5), 280–294 (2004).
   PubMedGoogle Scholar
• Goss JR, Goins WF, Glorioso JC. Gene therapy applications for the treatment of neuropathic pain. Expert Rev. Neurotherapeutics7(5), 487–506 (2007).
   PubMedGoogle Scholar
• Ferreira SH, Cunha FQ, Lorenzetti BB et al. Role of lipocortin-1 in the anti-hyperalgesic actions of dexamethasone. Br. J. Pharmacol.121(5), 883–888 (1997).
   PubMed Web of Science ®Google Scholar
• Sommer C, Schmidt C, George A, Toyka KV. A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy. Neurosci. Lett.237(1), 45–48 (1997).
   PubMed Web of Science ®Google Scholar
• Ribeiro RA, Vale ML, Ferreira SH, Cunha FQ. Analgesic effect of thalidomide on inflammatory pain. Eur. J. Pharmacol.391(1–2), 97–103 (2000).
   PubMed Web of Science ®Google Scholar
• Sommer C, Marziniak M, Myers RR. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain74(1), 83–91 (1998).
   PubMedGoogle Scholar
• Murata Y, Olmarker K, Takahashi I, Takahashi K, Rydevik B. Effects of selective tumor necrosis factor-α inhibition to pain-behavioral changes caused by nucleus pulposus-induced damage to the spinal nerve in rats. Neurosci. Lett.382(1–2), 148–152 (2005).
   PubMedGoogle Scholar
• Ghivizzani SC, Lechman ER, Kang R et al. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor α soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc. Natl Acad. Sci. USA95(8), 4613–4618 (1998).
   PubMed Web of Science ®Google Scholar
• Vale ML, Marques JB, Moreira CA et al. Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats. J. Pharmacol. Exp. Ther.304(1), 102–108 (2003).
   PubMedGoogle Scholar
• Lubberts E, Joosten LA, Chabaud M et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J. Clin. Invest.105(12), 1697–1710 (2000).
   PubMed Web of Science ®Google Scholar
• Milligan ED, Sloane EM, Langer SJ et al. Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain126(1–3), 294–308 (2006).
   PubMed Web of Science ®Google Scholar